Alexion says it has a 'robust pipeline of more than 20 development programs across seven rare disease franchises.' ...

The stock of Alexion Pharmaceuticals (NAS:ALXN, 30-year Financials) is estimated to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value ...

The stock of Alexion Pharmaceuticals (NAS:ALXN, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at ...

AstraZeneca will pay $39 billion to acquire Alexion in an immunology-driven deal that drives the British drugmaker closer to CEO Pascal Soriot's $40 billion revenue goal by 2023. (AstraZeneca) () Just ...

AstraZeneca stock tumbled Monday after the pharmaceutical giant announced its $39 billion plan to acquire rare-diseases biotech company Alexion Pharmaceuticals (ALXN). The deal brings to fruition ...

Alexion Pharmaceuticals (ALXN +0.00%) develops therapies solely for rare diseases, so you probably haven't heard of most of the conditions that it makes drugs for. However, for investors, it's worth ...

Alexion, on track to being acquired by AstraZeneca, plans to reach $9 billion to $10 billion sales by 2025. (Alexion) Toward the end of 2020, AstraZeneca splashed out $39 billion for Alexion to expand ...

Plaintiff Susanna Librandi claimed she was required to work remotely, and missed out on in-person opportunities because she did not comply with the vaccination requirement or weekly PCR testing.

A massive $39 billion acquisition by AstraZeneca of Boston-based Alexion Pharmaceuticals was announced Saturday morning, marking the largest tie-up of the year by dollar amount involving a U.S.-based ...